Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses

JAMA. 2011 Dec 21;306(23):2610-1. doi: 10.1001/jama.2011.1834.

Authors

J David Spence¹, Meir J Stampfer

Affiliation

¹ Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, 1400 Western Rd, London, ON, Canada N6G 2V2. dspence@robarts.ca

PMID: 22187282
DOI: 10.1001/jama.2011.1834

No abstract available

MeSH terms

Cardiovascular Diseases / blood
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic*
Data Interpretation, Statistical
Homocysteine / blood*
Homocysteine / drug effects
Humans
Kidney / physiopathology
Meta-Analysis as Topic
Methylenetetrahydrofolate Dehydrogenase (NADP) / genetics
Methylenetetrahydrofolate Dehydrogenase (NADP) / metabolism
Polymorphism, Genetic
Reproducibility of Results
Risk Assessment
Stroke / blood
Stroke / prevention & control
Vitamin B 12 / pharmacokinetics
Vitamin B 12 / therapeutic use
Vitamin B 12 Deficiency
Vitamin B Complex / pharmacokinetics
Vitamin B Complex / therapeutic use*

Substances

Homocysteine
Vitamin B Complex
Methylenetetrahydrofolate Dehydrogenase (NADP)
Vitamin B 12